Modulation of immune response by blood transfusion: evidence for a differential effect of allogeneic and autologous blood in colorectal cancer surgery

Shock
M M HeissF W Schildberg

Abstract

Even though blood transfusion-associated immunomodulatory effects have been reported, the basic immune mechanism is still not understood. Data from studies on the clinical effects of allogeneic blood-induced immunosuppression are contradictory. However, there are indications that autologous blood transfusion is not immunologically neutral but has intrinsic immunomodulatory potential. Therefore we investigated in vivo different immunological mediators in 56 randomized patients of a study comparing autologous and allogeneic blood transfusion in colorectal cancer surgery. Soluble IL-2 receptor, which is an indicator of general immune activation and the following immunologic refractory phase, indicated immunosuppression was more elevated at the seventh postoperative day in patients with allogeneic transfusions (p = .013) and autologous transfusions (p = .0003). The immunologic determination of TNF-alpha showed a significant postoperative increase in patients with autologous transfusions only (p = .0031). However, postoperative increase of soluble TNF-receptors p55 and p75 was also significant in patients transfused with allogenic blood (p = .022; p = .0014). The response to tetanus toxoid vaccination, an indicator of humoral immuni...Continue Reading

Citations

Aug 20, 2010·Intensive Care Medicine·Patrick MöhnleUNKNOWN Multicenter Study of Perioperative Ischemia (McSPI) Research Group
Dec 21, 2000·British Journal of Haematology·R M Winslow
Jun 5, 2004·Shock·Christopher C SillimanWalter L Biffl
Aug 19, 2004·Shock·Shawn J PelletierRobert G Sawyer
Apr 11, 2008·The Journal of Trauma·James R DunneMichael P Busch
Jun 12, 2009·The Journal of Trauma·James R DunneEric A Elster
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B RauW Franke
Jul 15, 2015·Revista española de anestesiología y reanimación·A Perez-FerrerF Gilsanz-Rodríguez
Apr 22, 2008·Transfusion·Stephanie A Snyder-RamosUNKNOWN MCSPI Research Group
Aug 8, 2001·The Journal of Urology·M BöhmE P Allhoff
Jul 21, 2015·The Journal of Surgical Research·Raghunandan Venkat, Marlon A Guerrero
Feb 14, 2002·The Journal of Surgical Research·James R DunneLena M Napolitano
Nov 21, 2007·Surgical Oncology Clinics of North America·Robert P Sticca, Jonathan A Sticca
May 12, 2004·Critical Care Clinics·Aryeh Shander
Jun 1, 2005·Anesthesiology Clinics of North America·Lawrence T Goodnough
Jul 5, 2006·Artificial Cells, Blood Substitutes, and Immobilization Biotechnology·Raul C Verdin-VasquezJorge Barroso-Aranda
Jul 13, 2000·Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery·A DietzH Maier
May 12, 2006·Transfusion·Ralf KargerVolker Kretschmer
Jun 22, 2002·The Cochrane Database of Systematic Reviews·D A HenryD Fergusson
Feb 23, 2002·Clinical Orthopaedics and Related Research·G ShulmanA G Hadjipavlou
Sep 4, 2020·Shock·Elise PretzschIrshad H Chaudry

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.